These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 29245103)
1. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration. Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103 [TBL] [Abstract][Full Text] [Related]
2. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Oliva EM; Harris AH; Trafton JA; Gordon AJ Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887 [TBL] [Abstract][Full Text] [Related]
3. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Manhapra A; Petrakis I; Rosenheck R Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543 [TBL] [Abstract][Full Text] [Related]
4. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097 [TBL] [Abstract][Full Text] [Related]
5. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170 [TBL] [Abstract][Full Text] [Related]
6. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs. Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022 [TBL] [Abstract][Full Text] [Related]
7. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386 [TBL] [Abstract][Full Text] [Related]
8. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Manhapra A; Quinones L; Rosenheck R Drug Alcohol Depend; 2016 Mar; 160():82-9. PubMed ID: 26804898 [TBL] [Abstract][Full Text] [Related]
9. Medications for management of opioid use disorder. Koehl JL; Zimmerman DE; Bridgeman PJ Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869 [TBL] [Abstract][Full Text] [Related]
10. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events. Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511 [TBL] [Abstract][Full Text] [Related]
11. Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder. Shiner B; Leonard Westgate C; Bernardy NC; Schnurr PP; Watts BV J Dual Diagn; 2017; 13(3):201-212. PubMed ID: 28481727 [TBL] [Abstract][Full Text] [Related]
12. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder. Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347 [TBL] [Abstract][Full Text] [Related]
13. Sex Differences in Opioid Use Disorder Prevalence and Multimorbidity Nationally in the Veterans Health Administration. Peltier MR; Sofuoglu M; Petrakis IL; Stefanovics E; Rosenheck RA J Dual Diagn; 2021; 17(2):124-134. PubMed ID: 33982642 [TBL] [Abstract][Full Text] [Related]
14. Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study. Iheanacho T; Issa M; Marienfeld C; Rosenheck R Drug Alcohol Depend; 2013 Sep; 132(1-2):122-6. PubMed ID: 23434041 [TBL] [Abstract][Full Text] [Related]
15. Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study. Marienfeld C; Iheanacho T; Issa M; Rosenheck RA Addict Behav; 2014 Feb; 39(2):434-8. PubMed ID: 23790742 [TBL] [Abstract][Full Text] [Related]
16. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362 [TBL] [Abstract][Full Text] [Related]
17. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what? Manhapra A; Stefanovics E; Rosenheck R Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914 [No Abstract] [Full Text] [Related]
18. Update on pharmacotherapy for treatment of opioid use disorder. Ayanga D; Shorter D; Kosten TR Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745 [TBL] [Abstract][Full Text] [Related]
19. Characteristics and current clinical practices of opioid treatment programs in the United States. Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836 [TBL] [Abstract][Full Text] [Related]
20. The association of opioid use disorder and homelessness nationally in the veterans health administration. Manhapra A; Stefanovics E; Rosenheck R Drug Alcohol Depend; 2021 Jun; 223():108714. PubMed ID: 33865213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]